Speciality Medicines Limited IPO Set to Launch on March 20, 2026
Speciality Medicines Limited, a prominent player in the marketing and distribution of specialty pharmaceutical products across various therapeutic areas, has announced the opening of its Initial Public Offering (IPO) on Friday, March 20, 2026. The company aims to raise up to ₹29.14 crore through this public issue, with shares slated for listing on the BSE SME platform. This move marks a significant step in the firm's growth trajectory, leveraging capital markets to fuel expansion and innovation in the healthcare sector.
IPO Details and Share Allocation
The issue comprises 23,50,000 equity shares, each with a face value of ₹10, offered within a price band of ₹117 to ₹124 per share. The allocation strategy is designed to cater to diverse investor segments, ensuring broad participation. Specifically, the equity share distribution includes:
- Qualified Institutional Buyers: Up to 21,000 equity shares
- Non-Institutional Investors: Up to 10,89,000 equity shares
- Retail Individual Investors: Up to 10,90,000 equity shares
- Market Maker: Up to 1,50,000 equity shares
The subscription window will remain open from March 20, 2026, to March 24, 2026, providing investors with a five-day period to participate in this offering.
Utilization of Proceeds and Strategic Goals
The net proceeds from the IPO are earmarked for several key initiatives aimed at bolstering the company's capabilities and market presence. These include:
- Establishing a dedicated Research and Development (R&D) Centre to drive innovation in pharmaceutical products.
- Facilitating product registration in international markets to expand global reach.
- Funding product development tailored for sale in overseas markets.
- Enhancing marketing and promotional activities to strengthen brand visibility.
- Meeting working capital requirements to support operational efficiency.
- Addressing general corporate purposes for sustained growth.
This strategic allocation underscores the company's commitment to advancing its portfolio in high-value therapeutic areas such as oncology, immunology, and neurology.
Leadership Insights and Market Positioning
Mr. Parth Goyani, Chairman & Managing Director of Speciality Medicines Limited, emphasized the company's foundational strengths, stating, "We have built Speciality Medicines Limited with a strong focus on providing access to high-value specialty pharmaceutical products across critical therapeutic areas. Our distribution network and customer relationships have enabled us to expand across over 20 states in India and several international markets." He added that the IPO represents a pivotal milestone, with proceeds set to enhance R&D, global registrations, and marketing efforts, thereby positioning the firm for sustainable long-term growth.
Echoing this sentiment, Mr. Brijesh Parekh, Founder & Director of Unistone Capital Private Limited, the Book Running Lead Manager for the issue, commented, "We are delighted to support Speciality Medicines Limited in this IPO. The company's diversified product portfolio and growing footprint in the specialty pharmaceuticals segment align well with market opportunities. The capital raised will further scale operations domestically and globally." The Registrar to the Issue is Skyline Financial Services Private Limited, ensuring smooth processing of the offering.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. The content is sourced from a syndicated feed, and no liability is assumed for its accuracy or completeness.
